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Abstract 
There is a great need for an at-home, simple, inexpensive, and noninvasive testing method to 
monitor the blood phenylalanine (Phe) levels of patients with PKU.  PKU is a rare genetic 
disorder that affects approximately one out 15,000 people, which results in dangerously high 
levels of Phe in the blood.  This project aims to show proof of concept for such a test, which is 
based upon a previously developed test method that was historically used to diagnose PKU from 
a urine sample. This redesigned test method represents the optimization of a little-understood 
reaction between Fe3+ ions and phenylpyruvic acid (PPA) that results in a color change.  PPA is a 
metabolic byproduct of elevated blood Phe levels, thus enabling it to be used as an indicator of 
this genetic disease.  The improved test increases sensitivity to the presence of PPA by two 
orders of magnitude over the previous method by including custom test substrates, controlled 
lighting conditions, and smart phone technology.  The process by which the test substrates were 
developed is presented, as well as their performance for the quantification of PPA concentration 
in a urine sample. The additional accuracy of the refined method is primarily provided by the 
implementation of a custom-made device to control light conditions combined with the 
measurement of color using a smart phone to photograph test samples combined with an RGB 
color application for color quantification.  The final test proposed is inexpensive, safe, and 
simple enough for a lay person to do at home.  Further optimization and calibration to 
individuals with PKU will be needed for the test to be commercially viable. 
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PKU is a rare genetic disease that causes the buildup of phenylalanine which results in 
severe developmental delays if not diagnosed and treated early in life1,2,3.  Treatment is nearly 
entirely diet based and requires rigorous monitoring of Phe levels in the blood to avoid the 
effects of the disease, especially in the cases of pediatric and maternal PKU1,4,5,6 .  Current 
monitoring methods are time consuming, complex, and invasive7.  This project attempts to show 
a proof of concept for a new method of non-invasive urine testing that could be used to monitor 
blood Phe levels in PKU patients.  This test is based on improving the sensitivity of a previously 
existing colorimetric diagnostic test for PKU marketed as Phenistix8.9 by regulating light 
conditions, improving the color changing substrate, and taking quantitative measurements of 
color by using a smart phone to digitally photograph the samples combined with a red-green-




2.1.  Disease and Treatment 
PKU (phenylketonuria) is a rare genetic condition that affects about 1 in 15,000 births in 
the US6.10.  Patients must be homozygous recessive to show symptoms and about 1-2% of the 
world population is a carrier for the gene7.   This condition is characterized by abnormally low 
levels of a hepatic enzyme called phenylalanine hydroxylase7,1.  This enzyme converts 
phenylalanine into tyrosine and without it phenylalanine levels in the body rise and build up in 
the neurological system.  Abnormally low levels of tyrosine are also observed11.  This causes 
severe developmental impairment if not treated, as well as seizures, microcephaly, 
hyperactivity, and EEG abnormalities2,12.  Less sever signs also include hypopigmentation and a 
musty odor12,7.   
The disease is usually managed by consuming a diet low in phenylalanine, which is 
supplemented by medical foods to provide the proper balance of nutrition1,5,6.  The goal is to 
keep blood Phe levels between 120-360 M.  Untreated individuals may have Phe levels 
exceeding 1200M, while non-PKU individuals have an average blood Phe concentration of 60 
M1.   PKU patients control their blood Phe levels by drinking Phe-free medical formulas that 
contain all of the other amino acids, which are available through medical suppliers. The medical 
food formula is then supplemented by controlled quantities of low protein foods, such as fruit 
and vegetables1,6.   Previously it was advised that the diet only be continued until age 10 when 
most development had been complete, but more recent research has found that continuing the 
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diet, and controlling Phe levels, is beneficial to PKU patients of all ages and is especially 
important in helping with depression, anxiety, attention deficit hyperactivity disorder, and 
headaches7,6.  Weekly blood tests are generally used in infants to monitor Phe levels and 
become less frequent as the patient ages1. 
The high Phe levels are most detrimental in the central nervous system, so some 
therapies have focused on trying to prevent Phe from permeating the blood brain barrier rather 
than controlling systemic levels11,13.  All large neutral amino acids use the same transport 
mechanism into the brain, so it is thought that simple competition with other amino acids may 
be able to prevent high neurological Phe levels11,13.  Therapy with tyrosine and tryptophan has 
been used with some success in PKU patients13, although it can be difficult to maintain high 
enough systemic levels of these other amino acids to see an effect in mental status11. 
Tetrahydrobiopterin (BH4 ) has been used to control blood Phe levels and has been 
demonstrated to increase platelet serotonin levels in PKU patients14.  Serotonin is an important 
neurotransmitter and low levels of it are correlated with high Phe levels and poor mood.  BH4 
therapy may be able to improve neurological symptoms by increasing serotonin and lowering 
Phe levels in addition to dietary therapy14. 
PKU is a genetic disease and so gene therapy has also been evaluated as an option for 
treatment, specifically targeting the liver where the deficient enzyme usually resides.  Limited 
success has been seen in the use of viral vectors in PKU mice, and it is thought that further 
reduction of the native viral genes is needed15.  Some of the successes with viral vectors were 
gender dependent (better results in male mice), which could lead to confusion in protocols in 
the future15.  The use of a non-viral vector, minicircle naked-DNA vectors have seen the most 
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success, with reduction of blood Phe levels and hypopigmentation for a year in PKU mice15.  
These therapies are still in animal testing stages and it is hard to predict when they may be able 
to help human patients. 
 Pharmacutical and gene therapy are promising for the treatment of PKU, but currently 
most patients are on a dietary monitoring program under the supervision of a doctor.   
2.2.  History of PKU Testing 
The devastating effects of phenylketonuria (PKU) were seen long before a disease was 
ever identified.  The disease caused severe mental impairments resulting in PKU patients who 
often needed to be institutionalized for the majority of their adult lives7,12.  The first hint at an 
underlying mechanism occurred when a desperate mother took her two children to a 
Norwegian biochemist and physician, Dr. Følling, in 19347,12.  At first he was unwilling to help, 
but the mother insisted that her children were originally developing normally, and gradually 
started emitting a musty odor and fell behind their peers in mental development, even losing 
milestones in coordination, a now common narrative from parents of PKU children12.  
Eventually, he tested the children for phenols in their urine using ferric chloride (FeCl3).  This test 
should have turned red or purple in the presence of phenols, but instead turned green.  Through 
careful chemical evaluation it was determined that the chemical causing the color change was 
phenyl pyruvic acid (PPA), a metabolic result of high levels of phenylalanine building up in the 
patients’ systems7,12,16. The exact mechanism of this color change is still unknown, but the rate 
of reaction is known to be affected by the concentration of both the ferric ions and the PPA, and 
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is sensitive to light2,10.  The color change is also temporary, going from a yellow-orange to a blue-
green, and back to a slightly darker yellow-orange within a few minutes of time2,10,17.  Attempts 
have been made to try to stabilize the color change by using different sources of Fe3+ ions or 
reducing temperature, with limited success17. The degree of color change is also be affected by 
urine pH and interference from phosphates10,18.   
All infants born in the United States have been tested for this condition since the 1960’s 
when effective treatment for the condition was finally available at a reasonable cost.  Before it 
was easy and cost effective to create a formula of amino acids excluding phenylalanine, low Phe 
diets were attempted, but usually resulted in malnutrition7.  With no available treatment, few 
children were tested for this condition until major developmental delays had already occurred.  
When the medical-food formula became cheaper to produce, through synthetic chemistry, 
infant screening programs were implemented in many developed nations to detect children 
with this genetic condition7. Originally these screening programs used the ferric chloride test, or 
slight variations on it, such as the Phenistix test, which involved easy-to-use strips of paper 
impregnated with ferric ions and other chemicals to optimize the color change reaction2,18.  The 
Phenistix test included an organic acid and a phosphate binding agent to get optimum color 
change regardless of changes in urine composition that occur with variations in diet8.  This test 
was easy to use, but couldn’t yield a diagnosis until about 3 weeks after birth when most infants 
had gone home from the hospital18. 
Similar to the ferric chloride based test was the DNPH (dinitrophenylhydrazine) based 
urine test.  This test also worked through a reaction with PPA, but instead of a green color, it 
created a yellow precipitate as an indication of unusually high levels of PPA2,9.  This reagent was 
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much more caustic than the ferric chloride solutions that could be used to yield similar results 
and was less stable for long term storage in labs, but some facilities preferred to use it9. 
  Some infants invariably fell through the cracks when trying to track them down for 
further testing, although some areas implemented programs where cards for urine samples to 
be dried on were mailed to new mothers and sent back to the hospital and others even had 
nurses make home visits a few weeks after birth7.  This screening process was further 
complicated by possible false negatives given by PPA based tests if the urine was contaminated 
with bacteria from feces, as could often be the case with diaper based testing19 and mothers 
often complained that getting a urine sample from an infant was too difficult to carry out20.  
There has also been criticism of this screening program for the damage that can be done by 
treating false positives with a low Phe diet21.  For example, there is a case study of two sisters 
who tested positive using the ferric chloride test for PKU, but in actuality had normal blood Phe 
levels, and merely excreted large amounts of Phe and its metabolic byproducts22.  Had these 
sisters been screened using the ferric chloride test, they may have been subjected to 
unnecessary dietary restriction in childhood. 
The iron chloride-based urine test was eventually replaced by the Guthrie blood test, 
which was invented by Dr. Robert Guthrie in 196218,21. The Guthrie test is still used in hospitals 
today to diagnose infants with PKU and was the first leap forward from the initial urine-based 
infant screening method.  It is a bacterial inhibition assay and relies on a heel prick to gather 
blood from an infant, which is then placed on a paper card for further processing1. It can give a 
reliable diagnosis within just a few days after birth; although if this first test is positive, a second 
test is carried out a few weeks later to ensure a correct diagnosis before treatment is started1.  
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The inventor of the test, Dr. Robert Guthrie, was an American bacteriologist and physician 
whose daughter suffered from developmental delays7,21.  Witnessing his daughter’s struggles, 
and those of children like her, led to his interest in PKU and ultimately the test for which he is 
best known7.  In the USA, the Guthrie test has largely been replaced with tandem mass 
spectroscopy; however, the original test is still favored in many places due to its ease to carry 
out and low cost7.   
Once a diagnosis has been made, the gold standard is HPLC testing of blood plasma for 
Phe levels to manage the condition with diet23.  This test requires trained technicians and a 
blood sample.  Often the patient can be tested at most once a week and the turnaround time is 
about a week for the test results to be returned to the patient’s family.  Many adults are tested 
less often than this1.  This misses many of the highs and lows that diet causes, which can be 
hourly on scale24.  A faster, layperson-administered test would make it easier for patients, and 
the parents of patients, to monitor the immediate effects of what they eat on their blood Phe 
levels, thus enabling their ability to more tightly control Phe levels on a daily basis.  This could 
reduce the need for doctor visits and help patients self monitor with greater accuracy25.    
Current research looking into novel PKU diagnositic and monitoring tests mainly fall into 
two catagories; those using enzymes26,27 and those using chromatography28,29.   Enzyme based 
tests have been developed for both serum26 and urine27 of PKU patients.  Serum based tests are 
unsuitable for home use, but may offer an alternative in a lab setting to the current process.  An 
enzyme based urine test could be used at home if the enzyme was sufficiently stabilized, but 
this is not the case currently.  At least two different novel methods of chromatography for the 
analysis of the urine of PKU patients have been developed since 200628,29.  These could possibly 
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be beneficial in a lab setting by quantifying multiple urine analytes relevant to PKU at the same 
time28,29.   The need for a non-invasive at-home monitoring test has not yet been met. 
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Chapter 3 
Objectives and Significance 
The primary objective of this research is to create an easy to use, at-home, inexpensive, 
urine-based test for PKU patients to monitor their blood Phe levels.  A urine test is noninvasive 
and likely to lead to higher patient compliance, especially for infants where blood draws are 
difficult and high Phe levels can do the most damage1,6,30.  It would also provide a means for 
daily Phe-level monitoring while waiting for blood Phe level results from the laboratory. 
A previous test for PKU diagnosis was the basis for this monitoring test.  Phenistix was 
patented in 1962 and used to diagnose infants with PKU8.  However, the lowest PPA value that 
can be detected by this method is 910 M (15 mg/dL) which is high enough that neurological 
damage is already being done7.  While other colorimetric tests had been used in the past3,7,9, this 
formulation was chosen for its relatively benign reagents, quick results, and easy readability.  
Also, unlike colorimetric tests looking for Phe directly, this method does not rely on enzymes, 
which may require careful handling and storage23,28,29.   Our test aims to modify this simple, 
urine-based, colorimetric test to heighten its sensitivity and accuracy through the use of 
controlled lighting, an RGB reading app on a smart phone, and a modified color-indicating 




The materials used for these experiments included a smart phone, synthetic and human 
urine, a version of the Phenistix formula, and several test substrates.  Details about each of 
these materials are included below to aid in replication of these experiments. 
The phone used for the test was an iPhone 5, using the app ColorHelper by <codete/> to 
read the RGB values off of the pictures taken.   
Preliminary experiments for test-method development were conducted using a 
synthetic urine, which was formulated from the major components of human urine as reported 
in the literature31 (full composition is provided in table 5.1).  Distilled water was used as the 
solvent.    
The liquid formula used to produce Phenistix was duplicated using the directions in 
USPO patent number 3,048,475 (full composition is provided in table 5.2)8.   
For testing, phenylpyruvic acid (PPA) was purchases from Amresco and creatinine was 
purchased from TCI. 
The light source for the light box were battery powered LEDs from SopoTek and were 
labeled as “7ft 20 LED warm white”. 
The other materials used in this research included creatinine test strips, filter paper, 
anodisks, paper towel sheets, oriented polymer substrates, and hydrogel bandages.  The 
creatinine test strips used were AdultaCheck6 tests produced by SCiTECK and Diagnostics, Inc. 
The filter paper used for the experiments were made by Whatman, grade 1, 10mm circles. The 
Anodisk substrates were made by Whatman and labeled as Anodisk 13, 0.2 µm membrane disk. 
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The white paper towels were made by Bounty™ and purchased at a local store. The oriented 
polymer substrate was harvested from pregnancy tests sold by Walgreens. The hydrogel 
bandages were manufactured for MPM medical, Inc. and went by the trade name “Cool Magic 




The experiments carried out utilized synthetic urine and Phenistix formula, the creation 
of which is outlined in the next section to aid in replication.  Experiments gradually evolved in 
complexity from simple vial tests, to a variety of custom substrate based tests.  The way each 
test was carried out was based on information learned from the previous test.  The methods 
used for each test are outlined below to add context for the results and to aid in replication. 
The synthetic urine was created by combining the inorganic urine analog components 
listed in Table 5.131 in 1.0 L of water, heating to 37 °C, and stirring until completely dissolved.  
The magnitudes of each component added are detailed in Table 5.1.  The solution was put 
through a sterile filter (500 mL rapid flow bottle top filter 0.2 M aPES membrane, 75 mm 
diameter, 45 mm neck, Nalgene, from thermo scientific) into an autoclaved glass bottle.  Human 





(g/mol) mg/L M 
Source 
Sodium Chloride NaCl 58.4 8001 0.14 Sigma Aldrich 
Potassium Chloride KCl 74.6 1641 0.02 Sigma Aldrich 
Potassium Sulfate K2SO4 174.3 2632 0.02 Amresco 
Magnesium Sulfate MgSO4 120.4 783 0.01 Sigma Aldrich 
Magnesium Carbonate MgCO3 84.3 143 0.002 Fisher 
Potassium Bicarbonate KHCO3 100.1 661 0.01 Amresco 
Potassium Phosphate K3PO4 212.3 234 0.001 Sigma Aldrich 
Calcium Phosphate Ca3(PO4)2 310.2 62 0.0002 Sigma Aldrich 
Urea H2NCONH2 60.1 13400 0.22 Fisher 
Table 5.1.  Constituents of synthetic urine31.  The fourth column shows the amount of chemical 
added to one liter of water in milligrams. 
The Phenistix formula was created following one of the formulations provided in the US 
patent for this testing system8.  This involved mixing a 20% ethanol solution and dissolving ferric 
ammonium sulfate, to provide Fe3+ ions; magnesium sulfate, a phosphate complexing agent; and 
cyclohexylsulfamic acid, to decrease the pH, into this solution while heating and stirring.  
Phosphates and high pH can interfere with color change, so this formulation is meant to provide 
optimal color change with the complexities of human urine.  The resulting solution was kept 






(g/mol) g/100mL M Source 
Ferric Ammonium Sulfate NH4Fe(SO4)2 ∙12H2O 482.25 5.8 1.20 Amresco 
Magnesium Sulfate MgSO4 120.37 8.9 7.39 Amresco 





Water H2O 18 80 Purified in Lab 
Ethanol C2H6O 46.07 20 Sigma Aldrich 
Table 5.2.  The composition of the Phenistix formula. The chart is divided into two sections by 
the shading.  Unshaded regions show the dry solutes while the shaded regions designate the 
liquid solvents.  The fourth column shows the amount of each chemical in grams added in a 100 
mL batch. 
Filter paper test substrates were prepared by soaking filter paper disks in the Phenistix 
formula until saturated (about 2 min.) and then laying them on a clean glass surface and drying 
in an oven at 100 °C for 20 min. 
Hydrogel bandages were prepared as test substrates due to their ability to hold liquid 
and their colorless transparent appearance.  These substrates were created in two ways.  Both 
methods involved drying the bandage at room temperature until completely collapsed (4 days), 
then soaked in the Phenistix solution for 24 hours to rehydrate and saturate the hydrogel with 
the reactant.  Then, half the bandages were dried in an oven for an hour at 100 °C to reduce 
their water content and the other half were used fully hydrated.    
Anodisks are a substrate made of alumina and manufactured so that they have oriented 
pores that open to the flat of the disks and run perpendicular to this surface.  While not 
absorbent, the orientated pores hold liquid so that the path length of light passing through is 
greater than that of filter paper of the same thickness.  Anodisk-based test substrates were 
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prepared by laying the Anodisks on a clean glass sheet and adding 20 L of Phenistix formula to 
each disk and then dried in an oven at 100 °C for 10 min.  This resulted in dry disks ready for 
testing, which had a uniform orange color.  
Ordinary white paper towels were also used as a test substrate by soaking in Phenistix 
formula until saturated (about 5 seconds) and drying at room temperature on a clean glass 
sheet.  This created an absorbent substrate with color changing ability. 
Test rolls were created by hand rolling 4 in. by 1 in. strips of white paper towel 
lengthwise and then tightly wrapping them in parafilm until securely fastened.  The rolls were 
then cut into disks with a razor blade so that they were about 2 mm high and 6 mm in diameter.  
These disks were dipped in the Phenistix formula until saturated and then taken out and laid flat 
on a clean glass plate to dry at room temperature for 24 hours.  The rolls were then stored in a 
beaker at room temperature.  
The light box was created by taking a 12 in. x 8 in. x 8 in. cardboard box and covering it 
in duct tape to make it light tight, except for the bottom, which was left open.  The inside was 
painted white to increase the reflection of light and reduce the appearance of shadows in 
photos taken inside the box.  A 7-ft. long string of LEDs was attached to the inside top perimeter 
of the box to provide light.  A section of wire without lights was used to attach the LED string to 
the power unit, which was taped to the outside of the box.  The wire was threaded along the 
inside of the box so as not to be visible in any test photos.  Baffles of cardstock were placed 
between the lights and the main chamber, parallel to the top of the box, to reduce glare from 
the LEDs, thus providing a diffuse lighting environment.  An opening was cut in the top of the 
box to allow enough space for the camera on an iPhone 5 to have an unobstructed view of the 
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bottom of the box.  The edges of the opening were covered in tape to add mechanical integrity 
and cover sharp edges.  Several pictures of the testing set up are provided in Figure 5.1. 
Figure 5.1. Light box in use.  An oblique view (left) shows the box on a table with the iPhone in 
use on top.  A top view (right) shows the screen of the phone viewing through the port in the 
top of the box to the illuminated the test samples below.  The different colors of the test 
samples are due to their exposure to different concentrations of PPA. 
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Figure 5.2. The light box when the lights are turned on.  The far-left photograph shows the 
power unit that is attached to the outside of the box powered by 3 AA batteries with a simple 
on/off switch.  The middle photograph shows the inside of the box from the bottom.  The 
baffles block direct light from the LEDs and small amounts of light can be seen leaking through 
defining the baffles in the picture.  The viewing port for the iPhone camera can be seen in the 
middle of the box.  The far-right photograph shows a close up of the LEDs inside the box.  The 
viewing port can be seen in the foreground for orientation.  The baffles form a partial ceiling in 
the photo.  The lights wrapped around the circumference of the box twice and the LEDs 
themselves tended to overlap as can be seen here. 
Initial tests were done without the aid of a light box and were not analyzed as 
thoroughly because the goal of this initial set of preliminary studies was to find an ideal 
substrate for testing.  Several historic tests involved the use of a liquid color change test instead 
of a paper substrate.  An analog of these tests was created by using 5 mL glass vials, which were 
each filled with 1.0 mL of either water or synthetic urine spiked with various amounts of PPA.  
100 L of Phenistix formula was then added to these vials (an estimated 4:1 Fe3+ to PPA molar 
ratio taken from literature to be ideal for color change) and the color change was observed at 5 
min. intervals and photographed without the use of the light box.   
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The first substrate used to try to simplify the test for home use was filter paper.  This 
paper was prepared as described above by soaking in Phenistix and drying in an oven.  Testing 
was done by adding 20 L of water or synthetic urine spiked with varying amounts of PPA to 
each disk of paper laying on a clean glass sheet and photographing at 5 min. intervals without 
the use of the light box. 
The hydrogel-bandage-based substrates were prepared as described above and the 
testing was carried out by laying 7 of each preparation type on a clean glass surface and adding 
20 L of synthetic urine spiked with varying amounts of PPA to each piece.  Photographs were 
taken at 5 min. intervals to monitor the color change. 
The Anodisks with dried Phenistix formula were tested by adding 20 L of synthetic 
urine spiked with varying amounts of PPA and photographing at 5 min. intervals to monitor the 
color change on a sheet of clean glass with white paper as a background without the use of a 
light box. 
Unrolled white paper towel substrates were testing in a manner similar to the Anodisks 
with 20 L of varying PPA concentration synthetic urine being added to each of seven pieces.  
Photographs were taken at 5 min. intervals to monitor the color change without the use of a 
light box. 
The paper towel test rolls were first tested without the use of the light box and used a 
clean glass sheet on top of white paper as a background.  However, this method was later 
further refined to include the light box and used a matte Teflon™ sheet background as outlined 
below.  Besides these changes, the procedure was exactly the same as described below.  
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Testing of the paper towel rolls was done by placing seven of the test rolls on a Teflon™ 
sheet.  Teflon™ was chosen because it is unreactive to the compounds used and is matte white 
in color, which was determined to be the ideal background for photographing the test samples.  
Tweezers were used to dip the test rolls one by one into shallow dishes of synthetic urine spiked 
with varying amounts of PPA, moving from lowest-to-highest to avoid contamination, until 
saturated (about 0.5 seconds).  An example of the saturated rolls is provided in Figure 5.3. 
Figure 5.3  Seven test parafilm-wrapped paper-towel rolls shortly after being dipped in synthetic 
urine spiked with PPA.  The rolls are arranged from highest PPA concentration to lowest in 
clockwise order starting with the sample in the far right middle of the circle. 
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The light box was then placed over the test rolls and the camera placed on top of that 
and the LEDs inside the box turned on.  A picture was taken with the preinstalled camera RGB 
color-app on the iPhone as quickly as possible and marked at time zero.  Pictures were taken at 
5 min. intervals to collect data.  In between pictures, the LEDs were turned off to reduce the 
amount of light the samples were exposed to because the reaction is light sensitive.   
The pictures were then analyzed using the ColorHelper app to obtain RGB values from 
the pixels near the center of each sample.  These RBG values were recorded and used to 
evaluate the color change capacity of each substrate that was tested.  The paper towel rolls with 
use of the light box had the most success so the data from those experiments was more 
thoroughly analyzed to assess accuracy.  Pictures of the app in use are shown in Figure 5.4. 
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Figure 5.4.  The picture to the left shows the screen of the ColorHelper app where the user 
selects the sample that they are interested in analyzing, which is in the center of the white 
crosshairs and is displayed in the top left corner of the screen.  The picture on the right shows 
the screen after the color selection has been made and the R, G, and B values can be read, as 
well as the hex code for the color. 
After the paper towel rolls were identified as the best testing system for synthetic urine, 
a similar procedure was used carry out experiments utilizing human urine spiked with PPA.  
Similar testing was also done with spiked synthetic urine samples that had been frozen for one 
week and thawed at room temperature to determine if this treatment would significantly 
influence the sample results if future samples needed to be frozen between acquisition and 
testing. 
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The creatinine strips were evaluated for their usefulness as a normalizing value for the 
hydration levels of human urine.  Commercially available test strips and several concentrations 
of synthetic urine spiked with creatinine were used for this test.  These test strips were soaked 
in their corresponding samples for 30 sec. before being photographed inside the light box 
following the same procedure as the PPA test rolls.  Again, the RGB values were acquired using 
the ColorHelper app and processed in Microsoft excel. 
Blind tests were carried out to test the ability of the testing system to identify the 
concentrations of unknown samples.  Three random samples were made by someone other 
than the tester, and each tested 3 times according to the same procedure as was used to 
evaluate the paper towel rolls.  Calibration curves were made on the same day, using the same 
concentrations as were used to evaluate the test substrates, and were used to analyze these 
samples.  Same day testing helped to control for variations in test-roll age and batch, and factors 
like lighting and humidity. 
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Chapter 6 
Results and Discussion 
6.1.  Assessment of Test Substrates 
Liquid ferric ion and PPA tests have been used the most historically, and are reliable7.  
However, they require precise measurements of all reactants if the color is to be interpreted in 
any quantitative way, which may be difficult to carry out in a home setting by a layperson32.  
Initial tests using a liquid-containing vial rather than a solid substrate sets the bar for the color 
change difference (i.e., gives the greatest color change) between samples of different PPA 
concentration.  The objective of these preliminary studies was to identify a substrate that 
provides the same level of color change as the liquid sample, if not more.  The photo below 
shows the color-change results for both a vial test and a filter-paper test carried out 
simultaneously for easy comparison. 
Figure 6.1.1.  Results for both the liquid vial and the filter-paper-based tests utilizing the 
Phenistix formula and synthetic urine 5 min. after the start of the reaction.  Each sample is 
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labeled with its PPA concentration in molarity.  The vial labeled “syn” is short for synthetic urine 
and contains no PPA. 
Water and synthetic urine were used for each type of test to understand if any of the 
most basic components of urine would interfere with the test.  Graphs showing the red (R) RBG 
values for the vials for both synthetic urine and water can be seen below.  The red values of the 
RBG values are shown because they tended to have the most reliable change in color with 
concentration.  Green values tended to mimic the red in trend, but with less space between 
points.  Blue values were not easy to draw trends from.  Graphs of the green and blue value 
results can be seen in the appendix.  As shown in Figures 6.1.2 and 6.1.3, despite the values in 
water having higher R values (indicating a lower degree of red absorbance, there is not a large 
difference between the changes as a function of PPA concentration for the synthetic urine and 
the water, thus indicating the changes in PPA concentration in the synthetic urine is qualitatively 
similar to that of the PPA in water.   
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Figure 6.1.2.  The red RBG values for vials of Phenistix added to seven concentrations of PPA in 
synthetic urine over the course of 30 minutes.  The key shows which marker shape corresponds 
























Figure 6.1.3.  The red RGB values for vials of Phenistix and seven concentrations of PPA in water 
over the course of 27 min.  The key shows which marker shape corresponds to each 
concentration of PPA in molarity. 
These two graphs both show that the darkest color change occurred at 5 minutes, 
where the RGB value was the lowest (when all RGBs are high the color is white, when all are 
zero, the color is black).  At the 5-min. time-point it can also be seen that the points are in the 
same order as the concentrations for the highest four concentrations (5 x 10-4 M, 2.5 x 10-4 M, 1 
x 10-4 M, 5 x 10-5 M) and zero.  9.1 x 10-4 M PPA is the lowest concentration that could be 
detected by the Phenistix strips8, so by using a liquid test where the path length of the light is 
longer, already improvements can be seen over the historic Phenistix test.  The goal remains to 
have a solid-based coupon test (i.e., instead of a liquid-based test) to make it easier for a lay 
person to use at home.  The results from the filter-paper test done simultaneously with the vials 
























provides much reduced sensitivity to changes in PPA concentration compared to the liquid vial 
samples. 
Figure 6.1.4.  The red RGB values for the filter paper treated with Phenistix and 8 different 
concentrations of water spiked with PPA.  The key shows which marker shape corresponds to 
























Figure 6.1.5.  The red RGB values for the filter paper treated with Phenistix and 8 different 
concentrations of synthetic urine spiked with PPA.  The key shows which marker shape 
corresponds to each concentration of PPA in molarity. 
When compared to the vial tests it clear that the filter paper results are not very 
sensitive to changes in PPA concentration.  It is difficult to discern any pattern at all, and the 
photograph (see Figure 6.1.1 above) shows that there is very little visible color change.  The 
filter paper is designed not to hold on to liquid and so only a very thin layer of the color-
changing chemical can be seen using this testing method.  A substrate that holds a higher 
volume of liquid was investigated next to see if solid-substrate sensitivity could be improved. 
Hydrogel bandages were an appealing substrate due to their availability, uniformity, and 
high water content.  Because the bandages are mostly water by weight when fully hydrated and 
transparent and colorless, it was hypothesized that they would be able to showcase the color 
























bandages that were treated with Phenistix formula are shown below 5 min. after exposure to 
synthetic urine spiked with PPA over a range of concentrations. 
Figure 6.1.6.  Fully hydrated hydrogel bandages with droplets of synthetic urine spiked with 
varying concentrations of PPA on their surface 5 min. after the PPA test solution was added.  
Concentration goes from high on the left to low on the right 
Figure 6.1.7. Dehydrated hydrogel bandages with droplets of synthetic urine spiked with varying 
concentrations of PPA on their surface 5 min. after the PPA test solution was added.  
Concentration goes from high on the left (5 x 10-4 M) to low on the right (no PPA). 
As clearly shown from these photographs, the synthetic urine was not absorbed into the 
bandage within the 5 min.  timeframe.  This resulted in droplets on their surfaces with different 
thicknesses, leading to unreliable colorimetric readings with low sensitivity to PPA concentration 
compared to the liquid-vial test condition.  Graphs of these readings are shown below. 
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Figure 6.1.8.  The red RGB values for the fully hydrated hydrogel bandage treated with Phenistix 
solution for seven different concentrations of PPA-spiked synthetic urine over 20 min.  The key 
























Figure 6.1.9.  The red RGB values for the dried hydrogel bandage treated with Phenistix solution 
for seven different concentrations of PPA-spiked synthetic urine over 10 min.  The key shows 
which marker shape corresponds to each concentration of PPA in molarity. 
Although having low sensitivity, the fully hydrated hydrogel bandage showed patterns 
closely resembling the vial tests with respect to the lowest RGB values at 5 min. after the 
beginning of the test.  These results indicate that the ferric ions were able to migrate out of the 
gel matrix to react with the droplet rich in PPA.  At the end of the test the droplets were cleaned 
off of the gels and there was not a color change in the gel itself, suggesting the PPA did not 
permeate into the gel.  The dried bandages adsorbed more of the synthetic urine compared to 
the saturated hydrogel samples, with a less-regular droplet shape, but only provided a color 
change pattern for the highest concentration of PPA compared to the zero value.  While the fully 
hydrated bandage worked as well as the filter paper with synthetic urine, the results were highly 
dependent on the drop shape and size, which could be difficult to regulate in a home setting.  























wicked-sample capacity (i.e., sample volume) would provide enhanced sensitivity to PPA 
concentration compared to the filter and hydrogel substrates. 
To provide these conditions, Anodisks were evaluated next as a sample substrate that 
should provide faster wicking and higher sample capacity.  Anodisks are a type of alumina that is 
formed into thin brittle disks with oriented pores.  These pores allow the Anodisks to hold small 
volumes of fluid in vertical channels where the fluid can be observed.  These disks were 
saturated with the liquid Phenistix formula, dried, and then small volumes of PPA spiked 
synthetic urine were added.  A photograph of this testing set up is shown in Figure 6.1.10. 
Figure 6.1.10.  Anodisks pretreated with Phenistix 5 min. and then exposed to several different 
synthetic urine with varying concentration of PPA.  PPA concentrations move from high on the 
left (5 x 10-4 M) to low on the right (no PPA).  
As clearly observed visually from the photograph shown in Figure 6.1.10, even synthetic 
urine with no PPA (right-most disk) creates a color change in the Anodisks treated with Phenistix 
formula.  This was further investigated by adding distilled water to one of the Phenistix treated 
disks and finding that the color change still occurred leading to the belief that this phenomenon 
is based on a physical color rather than a chemical reaction.  The test was still analyzed to see if 
the Anodisks would be a suitable substrate for this test.  The results of this analysis are shown in 
Figure 6.1.11. 
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Figure 6.1.11.  The red RGB values for the Anodisks pretreated with Phenistix formula at up to 
10 min. after exposure to synthetic urine spiked with different amounts of PPA.  The key shows 
which marker shape corresponds to each concentration of PPA in molarity. 
Despite the small visual difference between the samples, the readings taken off of the 
photographs reveal that there is some difference in color change correlating to PPA 
concentration that reaches its peak around 2 min. after the addition of the urine analog and has 
almost completely faded after 10 min.  While the Anodisks show some success, they still don’t 
compare to a simple liquid test and are very brittle, making practical use difficult without 
breaking them.  An ideal test substrate would be more mechanically robust. 
White paper towels fit the ideal test substrate criteria by being fast wicking, highly 
absorbent, colorless, and mechanically robust.  Initial tests also revealed no side reactions 
interfering with color change as printer paper did when coming into contact with Phenistix 























solution, dried, and had small amounts of synthetic urine with varying amounts of PPA added.  A 
photograph of the testing set up and the resulting color changes are shown in Figure 6.1.12. 
Figure 6.1.12. White paper towel sheet sections that have been treated with Phenistix formula 
and dried 5 minutes after synthetic urine with varying amounts of PPA had been added.  
Concentrations vary from high on the left (5x10 -4 M) to low on the right (no PPA).  The yellow or 
orange color is the dry sections of the paper towel, while the white or blue sections are the 
wetted areas, as the amount of PPA solution added did not fully saturate the paper towel. 
This testing substrate was highly absorbent and the synthetic urine spread to create a fairly even 
thickness of liquid giving an even color.  However, the pattern on the paper towel created 
shadows that made measuring the color from a photograph difficult.  Trying to pick a 
representative color patch on each sample, readings were taken and are presented in Figure 
6.1.13. 
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Figure 6.1.13.  The red value of the RGB readout of the test section of the paper-towel substrate 
at three time intervals after the synthetic urine spiked with several concentrations of PPA were 
added.  The key shows which marker shape corresponds to each concentration of PPA in 
molarity. 
As shown in Figure 6.1.13, while the lowest red value is at 5 min., the points are the 
most spread out at 0 minutes.  The highest 3 concentrations and the zero value are in order for 
the 0 and 5-minute time points.  The paper towel substrate also became fairly brittle and fragile 
when the Phenistix was dried onto it, so some refinement was needed. 
While the individual paper towel sheet substrates provided fast wicking, the sample 
volume that could be absorbed was still very low.  Therefore it was decided to enhance the 
sample volume by increasing the thickness of the paper towel substrate, but in a manner to still 
provide very fast wicking of the synthetic urine test sample into the substrate.  The final 























to create disks, which were then dipped in Phenistix solution and dried.  These will be referred 
to as test rolls.  Several different materials were used to make test rolls, but the paper towel had 
the most success so it will be the only one discussed in detail here.  The rolls attempted to 
combine all of the positive traits of other substrates by being cheap, colorless, absorbent, having 
vertically oriented channels, smooth texture for photography, and being mechanically robust.  
When one surface of the roll was dipped in liquid, the full saturation of the roll was nearly 
immediate.  The parafilm prevented any trouble with the paper becoming brittle after Phenistix 
formula was dried on the substrate, although it did prevent oven drying, due to its low melting 
point.  A photograph of testing using the rolls as substrate is shown in Figure 6.1.14.  The 
mechanical robustness of the rolls as well as their quick wicking ability allowed the rolls to be 
dipped in the synthetic urine samples spiked with PPA leading to full saturation and even color. 
Figure 6.1.14.  The test rolls under normal lab lighting on a sheet of clean glass with white paper 
for a background 5 min. after being dipped in varying concentrations of synthetic urine spiked 
with PPA.  PPA concentrations go from high on the left (5x10 -4 M) to low on the right (no PPA). 
Even with the naked eye the color gradient of the samples is clearly apparent as the 
concentration of PPA decreases, with the range of color intensity obviously being much greater 
than any of the prior substrate materials that were tested.  The highest concentration is much 
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darker than previous solid substrate tests, and even the liquid test.  The RGB readings confirm 
this and provide quantitative red absorbance values and are presented in Figure 6.1.15. 
Figure 6.1.15.  The red RGB values for the test rolls under normal lighting conditions at 5 min. 
intervals after being dipped in synthetic urine spiked with different concentrations of PPA.  The 
key shows which marker shape corresponds to each concentration of PPA in molarity. 
Figure 6.1.15 shows that the red absorbance values are very widely spaced and get 
much lower than with any other test substrate.  As time goes on the colors of each roll start to 
move towards a central value, but more slowly than they did with the thinner substrates.  While 
the darkest color is reached at 0 minutes, immediately after dipping the rolls in synthetic urine 
and PPA, the points are most evenly spaced at 5 min. with all but the 5 x 10-6 M values in the 
same order as their concentrations.  This response is much better than any other substrate.  





















camera focusing, and the angle of the camera relative to the samples made it difficult to 
compare objective RGB values from one run to the next.   
The use of a light box described in the methods section made tests using these rolls 
much more repeatable so that tests run on different days would give similar results, allowing for 
statistical comparison.  This was the final test set up that was evaluated for its ability to detect 
PPA in the urine of PKU patients in a reliable and clinically relevant manner. 
6.2.  Additional Substrates 
In addition to the substrates discussed above, several trials were done with substrates 
that incorporated polyacrylic acid (PAA), which is a superabsorbent polymer sometimes used in 
diapers.  PKU testing centers around infants because they are the patient population most at 
risk for adverse effects from high blood Phe levels. We therefore explored the idea of 
developing a substrate that could be used to collect a urine sample directly from a wet diaper. 
Experimenting with the idea of using a diaper directly as a test substrate led to the idea of 
adding PAA to some of the existing substrates to improve their absorbency.  PAA was added to 
the hydrogels bandages, white paper towels, and test rolls.  This was done by dissolving PAA 
into the Phenistix solution, then treating the substrates the same way their non-PAA 
counterparts were.  This modified solution was also tried with the wicking center of a pregnancy 
test, which has many of the same desirable characteristics as the paper towel rolls, mainly 
colorlessness, oriented channels and mechanical robustness.  It also had the added benefit of 
being commercially available so differences between samples was lessened.   
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Ultimately the pregnancy test polymer idea was dropped due to it being more expensive 
than the paper towels, performing slightly less well, and being very narrow in one dimension 
which made handling and photographing difficult (data not shown).  The PAA also did not have 
the intended effect of adding absorbency to any of the substrates in any observable manner, 
and for the most part masked the color change taking place.  When the PAA was mixed with the 
Phenistix formula it turned the golden-orange colored solution a deep orange-red color.  This 
color persisted during testing which made the color change due to the ferric ion and PPA 
reaction less noticeable to the naked eye and when analyzed using the smart phone app and 
photography (data not shown). 
Modifications to the Phenistix formula were also undertaken to help the filter paper 
substrate perform better.  One test was run where the amount of ferric ions was doubled, and 
another was run where the Phenistix solution was added to the filter paper, dried, and then 
added again and dried.  Both of these techniques hoped to increase the amount of color 
changing agent and give better color changing results.  This ultimately did not help, and the 
results were nearly identical to the standard Phenistix formula on the filter paper and it was 
decided that optimizing the substrate was going to be more fruitful than optimizing the 
Phenistix solution. 
Several substrates were tried in a rolled form, due to the success of the paper towels.  
These included filter paper, absorbent sheets taken from the spill kit in the lab, “amoeba” fibers 
of different thicknesses (fiber with irregular cross-section like the shape of an amoeba, thus 
providing high wicking ability), and cigarette filters.  The filter paper could not be cut by the 
razor once rolled so disks could not be made.  The sheets from the spill kit had colors that 
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interfered with getting accurate RGB readings, and had a quilted architecture that prevented 
oriented channels from forming reliably.  The amoeba fibers, when made into nonwoven sheets 
and rolled, had difficulty holding onto the fluid and the Phenistix solution tended to form 
crystals with limited solubility during testing.  The cigarette filters turned out to be hydrophobic 
and would not absorb the Phenistix solution.   Each of these substrates helped to form the 
definition of the test substrate that would ultimately work. 
6.3.  Evaluating the Final System 
A synthetic urine analog was used as the solution for a set of experiments to test the 
ability of the system to detect PPA.  This allowed for a complete knowledge of what was in the 
sample so that an accurate calibration curve could be created.  Six runs of the test were done 
and each test included 7 different concentrations of PPA.  The RGB values were recorded for 
each sample and normalized by the background value of the photograph.  In order to tell if the 
test was detecting a difference between concentrations a Student’s t-test was run comparing 
each set of readings for one concentration to the nearest concentration set that was measured.  
This test should answer the question of whether or not the mean reading of each concentration 
is statistically different from readings of similar concentrations.  The results are summarized in 
Table 6.3.1. 
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Synthetic urine t-tests 
set 1[M PPA] 5x10^-4 2.5x10^-4 1x10^-4 5x10^-5 1x10^-5 5x10^-6 
set 2[M PPA] 2.5x10^-4 1x10^-4 5x10^-5 1x10^-5 5x10^-6 syn 
red 0 minutes 0.121 0.011 0.001 0.000 0.017 0.001 
red 5 minutes 0.070 0.003 0.002 0.000 0.008 0.081 
green 0 
minutes 
0.090 0.010 0.000 0.001 0.015 0.002 
green 5 
minutes 
0.041 0.004 0.003 0.000 0.025 0.526 
blue 0 
minutes 
0.153 0.135 0.006 0.056 0.621 0.375 
blue 5 
minutes 
0.064 0.025 0.041 0.534 0.181 0.497 
Table 6.3.1. Student’s t-test results for synthetic urine comparisons of neighboring 
concentrations.  Values for the rows labeled “set 1 [M PPA]” and “set 2 [M PPA]” denote which 
concentrations of PPA are being compared in that column.  The row labels with a color and time 
denote whether the reading was the red, green, or blue value from the RGB code and what time 
the reading was taken.  Values of p < 0.05 are highlighted and show statistical significance at the 
95% confidence interval. 
The results summarized in Table 6.3.1 show that a PPA concentration of as little as 5 x 
10-6  M can be detected for red and green values at 0 minutes.  Further optimization of this
method should look for the greatest color difference between these two time points and use 
either a red or green reading.  Concentrations of as little as 1 x 10-5 can be detected in both red 
and green values at 5 min.  Blue values did not provide a sensitive measure of PPA 
concentration.  The test had difficulty differentiating larger values of PPA, which is probably due 
to the darkness of these samples causing very low RGB values, sometimes as low as zero, giving 
little room for difference between raw data points.  If the test is to be optimized for larger 
values of PPA it may require brighter lighting or a more dilute version of the Phenistix formula to 
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be used in creating the test rolls.  The goal in creating these test rolls was to push the limit of 
PPA detection to its lowest level with this method, so lower concentrations were focused on 
when designing the test.  This test successfully detected PPA at concentrations two orders of 
magnitude lower than the original Phenistix test. 
6.3.a. Results Using Actual Human Urine 
Once the test had shown the ability to detect PPA at very low concentrations in 
synthetic urine, human urine samples were obtained and spiked with PPA. The same procedure 
was then followed as in the synthetic urine to evaluate if the test could detect PPA with the 
added complexities of actual urine.  The chart below summarizes the results of Student’s t-tests 
carried out to see if the mean of each normalized concentration was significantly different from 
the concentrations closest to it. 
Real Urine t tests 
set 1 [M PPA 
added] 
5x10^-4 2.5x10^-4 1x10^-4 5x10^-5 1x10^-5 5x10^-6 
set 2 [M PPA 
added] 
2.5x10^-4 1x10^-4 5x10^-5 1x10^-5 5x10^-6 syn 
red 0 
minutes 
0.004 0.005 0.026 0.005 0.429 0.393 
red 5 
minutes 
0.007 0.006 0.005 0.010 0.326 0.927 
green  0 
minutes 
0.012 0.006 0.020 0.006 0.532 0.680 
green 5 
minutes 
0.010 0.009 0.033 0.134 0.313 0.843 
blue 0 
minutes 
0.149 0.008 0.533 0.835 0.763 0.316 
blue 5 
minutes 
0.048 0.193 0.254 0.974 0.185 0.963 
 Table 6.3.2. Student’s t-test results for human urine comparisons of neighboring 
concentrations.  Values seen the rows labeled “set 1 [M PPA] added” and “set 2 [M PPA] added” 
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denote which concentrations of PPA are being compared in that column.  The row labels with a 
color and time denote whether the reading was the red, green, or blue value from the RGB code 
and what time the reading was taken.  Values of p < 0.05 are highlighted and show statistical 
significance at a 95% confidence interval. 
Table 6.3.2 shows similar results to those of the synthetic urine.  The smallest amount of 
PPA that could be detected was in the red and green readings at 0 minutes, although in this case 
the red reading at 5 minutes could also detect PPA at a concentration of 1 x 10-5.  The amount of 
PPA already present in the human urine before it was spiked was unknown and makes these 
results harder to interpret than the synthetic urine, but it seems the test has a lower detection 
limit with the added complexities of human urine.  This could be further clarified in experiments 
where the PPA concentration is independently measured and compared to the test values.  
6.3.b.  Effect of Freezing/Thawing on PPA Measurement 
A vial of PPA-spiked synthetic urine was frozen for one week and thawed to test 
whether freezing and thawing affects the concentration of PPA in a synthetic urine sample.  The 
thawed sample was diluted with synthetic urine to make a standard set of concentrations that 
could be easily compared to measurements taken with the same sample before it was frozen.  
Four runs of each sample were measured and the results of the t-test comparing before and 
after freezing measurements is presented in Table 6.3.3. 
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Student’s t test--never frozen vs thawed 
PPA [M] 5x10^-4 2.5x10^-4 1x10^-4 5x10^-5 1x10^-5 5x10^-6 0 
red 0 0.113 0.212 0.793 0.983 0.187 0.818 0.322 
red 5 0.051 0.192 0.917 0.227 0.301 0.333 0.122 
green 0 0.164 0.202 0.702 0.978 0.488 0.787 0.449 
green 5 0.017 0.147 0.941 0.393 0.496 0.464 0.385 
blue 0 0.328 0.299 0.610 0.297 0.651 0.476 0.422 
blue 5 0.326 0.389 0.595 0.927 0.320 0.264 0.648 
Table 6.3.3.  Student’s t-test results comparing synthetic urine samples spiked with PPA, before 
and after a freeze-thaw cycle.  The highlighted value is the only one with a p-value of less than 
0.05, meaning that all the rest of the comparisons are not indicated to be statistically different 
from each other. 
Only one set, the one comparing pre- and post-freeze values for the green reading at 5 
minutes at the concentration of 5 x 10-4 M PPA shows a significant difference.  All 41 of the 
other comparisons showed no difference between the means of each set.  The frozen and 
thawed synthetic urine samples show that the ability of color change to take place is not 
affected by the freezing or thawing process.  Therefore, for future studies involving the 
collection and testing of actual human urine samples, samples should be able to be frozen for up 
to a week-long period of time and then thawed prior to PPA analysis without affecting the 
measurement of PPA that was in the fresh urine sample. 
6.3.c.  Creatinine Measurements 
As documented in our studies, the Phenistix formula rolls can be used to measure the 
concentration of PPA in a urine sample over a broad range of PPA concentration.  But in order to 
correlate these values to the blood Phe levels in a patient, they must be normalized by another 
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metabolite in the urine to account for differences in urine hydration.  The metabolite that was 
chosen in this case was creatinine because it is a metabolic standard in urine testing and has a 
fairly constant excretion rate from the kidney independent of factors such as the amount of 
water consumed by the patient over a given period of time33, and its measurement after 
repeated freezing and thawing is largely unchanged34.  Thus normalization of PPA concentration 
in a urine sample by the concentration of creatinine can be used to normalize the urine sample 
for dilution effects due to the level of patient hydration.  Testing was therefore conducted to 
evaluate the ability to quantitatively determine creatinine concentration in urine by spiking 
synthetic urine with known amounts of creatinine followed by the use of color-indicating 
creatinine test strips. The resulting color change was then quantified using the same developed 
smartphone/RGB app and lightbox system that we developed for PPA concentration 
determination.   
Commercially available colorimetric creatinine test strips were used with the light box 
and synthetic urine samples to first create a calibration curve.  Theoretically, both the PPA and 
creatinine color tests could be done at the same time from the same photograph to measure 
each concentration using calibration curves between color and concentration.  These values 
could be used to calculate a ratio between these two urine solutes.  The creatinine strips 
unfortunately showed a great deal of variability as can be seen in the picture below where all 
three strips were exposed to the same high concentration of creatinine for 30 seconds. 
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Figure 6.3.1.  Photograph of three commercially available creatinine detection strips that had 
been exposed to 400 mg/dL of creatinine in synthetic urine for 30 seconds and let sit for another 
30 seconds.  Blotchy coloring can be seen on each strip as well as variation between the strips. 
Even with these challenges, a calibration curve was made using the creatinine test 
strips, the light box, and the color identification app.  This calibration curve can be seen below, 
along with a line of best fit. 
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Figure 6.3.2.  Calibration graph for creatinine in synthetic urine.  Readings taken after 5 min. 
The red value was chosen to be used for the calibration of the creatinine strips because 
it displayed the most linear behavior.  A linear fit for the data has an r-squared value of 0.93.  
The strips tended not to form a uniform color across the test pad and further refinement of this 
part of the test may be necessary for an accurate approximation of patient blood values. 
Nearly a year prior to the tests seen above, the creatinine strips were evaluated by 
adding 10 L of synthetic urine with the same added creatinine concentrations as shown in 
Figure 6.3.2 to the test pad.  A photograph of this test can be seen below. 



























Figure 6.3.3.  The creatinine test strips 60 sec. after 10 L of each solution was added to the 
corresponding test pad.  The arrow designates the test pad for creatine (the other test pads 
were for different analytes not relevent to this study).  The numbers above each strip designate 
the concentration of creatinine and go from 0 mg/mL on the far left to 400 mg/mL on the far 
right. 
This photograph shows that originally these test strips created a readable color that was 
clearly uniform and sensitive to creatinine concentration.  These tests did not use the light box 
and were not taken by dipping the strips into the synthetic urine sample, so they were not 
representative of the final testing system.  Unfortunately, subsequent tests with these test strips 
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provide inconsistent results compared to the initial tests, thus indicating that some aging 
phenomenon had occurred that reduced their performance.  New strips were therefore 
ordered, hoping that newer strips would exhibit the behavior seen a year prior. However, the 
strips that arrived were from the same batch as the ones already possesed, and showed the 
same inconsistent results considered to be due to aging as with the prior set of creatinine strips, 
even though the expiration date for the strips was nearly a year in the future.  Perhaps working 
with the distributor could help to ensure a higher quality control standard for this more 
quantitative use for the strips than was intended by the manufacturer. 
6.3.d. Correlation Between Urine PPA and Blood Phe Concentration 
Several studies have been done looking at the correlation between PPA and creatinine 
levels in the urine of PKU patinets and their blood Phe levels.  One such study was used to 
create a calibration curve to relate these values so that the measured values from our test could 
be connected to patient Phe levels.  A reproduction of this study’s data is provided in Figure 
6.3.4 along with a line of best fit33 
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Figure 6.3.4.  The correlation between PPA concentration normalized by creatinine (Cre) in the 
urine [mole PPA/mmole Cre] and the concentration of Phe [mmole] in the plasma of PKU 
patients between the ages of 2 and 12 years33. 
Figure 6.3.4 shows that there is a large amount of scattering in the data, which is not 
uncommon for biological measurements.  Literature shows that the relationship between these 
values is dependent on age and individual differences1,7,33 .  PPA stops being produced when 
blood Phe levels are below about 0.25 mM and renal clearance of PPA plateaus at about 1.2 
mM33, and even renal clearance of Phe is dependent on age35.  This limits the usefulness of a 
generalized calibration curve for a large population with varying levels of control over their PKU 
diets.  The data is fairly linear, and allows for a fit to be found that will be used in the blind tests 
to demonstrate the ability of our test to predict blood Phe levels.  Future applications of this test 
will likely include individual calibration curves for each patient after several routine visits to their 
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local PKU center where blood and urine composition measurements can be made with great 
precision. 
6.3.e  Blind Tests for PPA Analysis Method 
Blind tests were completed to show proof-of-concept for how the test will work in 
patients.  Readings of creatinine and PPA unknowns were taken using the same method used to 
test the paper-towel-roll substrates.  The calibration curves were created and used to calculate 
an estimated concentration for the PPA and creatinine, which were then paired and used to 
estimate a theoretical blood Phe value using a correlation taken from literature.   
Three samples with unknown PPA concentration were created (unknown to person 
conducting the PPA concentration analysis), labeled A, B, and C.  The test was repeated 3 times 
for each sample and the RGB values were averaged among the runs and normalized by the 
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  These normalized values are presented in Table 6.3.4.  
 Table 6.3.4. The normalized and averaged RGB values for PPA blind samples A, B, and C at zero 
and five minutes after the first reading. 
Blind PPA samples A B C 
Red 0  minutes 13.56 31.85 70.11 
 Red 5 minutes 18.50 52.92 84.98 
Green 0 minutes 15.70 36.85 69.82 
 Green 5 minutes 23.81 56.62 83.75 
 Blue 0 minutes 7.81 11.52 16.55 
 Blue 5 minutes 9.74 18.73 15.57 
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Both linear interpolation and a logarithmic fit were used to estimate the PPA 
concentration from a calibration curve of the RGB values vs. PPA concentration, resulting in the 























3.75E-04 4.46E-04 7.08E-05 18.88 3.88E-04 1.30E-05 3.47 
red 5 
min 
3.75E-04 4.31E-04 5.61E-05 14.96 3.89E-04 1.36E-05 3.63 
green 
0 min 
3.75E-04 4.43E-04 6.83E-05 18.20 4.00E-04 2.46E-05 6.56 
green 
5 min 
3.75E-04 4.12E-04 3.68E-05 9.81 3.72E-04 -2.54E-06 -0.68
blue 0 
min 
3.75E-04 3.58E-04 -1.70E-05 -4.53 3.62E-04 -1.28E-05 -3.42
blue 5 
min 
3.75E-04 4.57E-04 8.23E-05 21.94 3.92E-04 1.75E-05 4.66 
Table 6.3.5. The estimated values for unknown PPA sample A, as well as percent errors and the 
actual concentration for 0 and 5 minute readings for red, green, and blue readings using linear 
interpolation and a logarithmic fit from the calibration readings. 
The data from sample A suggests that the logarithmic fit of the calibration curve data is 
better than the linear interpolation for estimating the PPA concentration of an unknown 
sample.  It is difficult to tell from this unknown whether a reading at 0 or 5 minutes is the best 
for getting the most accurate estimate. 

























1.50E-04 1.97E-04 4.70E-05 31.31 2.46E-04 9.60E-05 64.03 
red 5 
min 
1.50E-04 1.47E-04 -3.16E-06 -2.11 1.93E-04 4.30E-05 28.68 
green 
0 min 
1.50E-04 2.01E-04 5.10E-05 33.99 2.33E-04 8.31E-05 55.40 
green 
5 min 
1.50E-04 1.52E-04 1.71E-06 1.14 1.83E-04 3.34E-05 22.26 
blue 0 
min 
1.50E-04 2.08E-04 5.85E-05 39.00 2.55E-04 1.05E-04 70.28 
blue 5 
min 
1.50E-04 6.67E-05 -8.33E-05 -55.53 2.02E-04 5.16E-05 34.38 
Table 6.3.6.  The estimated values for unknown PPA sample B, as well as percent errors and the 
actual concentration for 0 and 5 minute readings for red, green, and blue readings using linear 
interpolation and a logarithmic fit from the calibration readings. 
These data from sample B show the most accurate readings for red and green values 
taken at 5 minutes and PPA values estimated using the linear interpolation method.  From 
previous experiments it was determined that the blue readings were fairly unreliable and are 
unlikely to be used for the final method of determining patient health levels.   
Unknown sample C had the lowest concentration, and the lowest overall accuracy.  Its 
























6.25E-05 7.34E-05 1.09E-05 17.38 1.15E-04 5.23E-05 83.68 
red 5 
min 
6.25E-05 7.50E-05 1.25E-05 20.02 1.05E-04 4.24E-05 67.83 
green 
0 min 
6.25E-05 7.40E-05 1.15E-05 18.34 1.08E-04 4.59E-05 73.48 
green 
5 min 
6.25E-05 7.51E-05 1.26E-05 20.16 9.79E-05 3.54E-05 56.68 
blue 0 
min 
6.25E-05 1.32E-04 6.90E-05 110.46 1.56E-04 9.36E-05 149.80 
blue 5 
min 
6.25E-05 1.09E-04 4.66E-05 74.48 2.56E-04 1.93E-04 308.96 
Table 6.3.7. The estimated values for unknown PPA sample C, as well as percent errors and the 
actual concentration for 0 and 5 minute readings for red, green, and blue readings using linear 
interpolation and a logarithmic fit from the calibration readings. 
For unknown sample C, the linear interpolation method for the red and green readings 
seem to be the most accurate, and the 0 min. readings the most accurate out of those.   
Each unknown sample gives a different conclusion on the most accurate way to 
estimate the PPA value from the readings taken.  Sample A suggests using a logarithmic fit to the 
data, while B and C suggest linear interpolation as the best method.  Samples A and B suggest 
that the 5-min. reading is better than a 0 min. reading, while C shows a better accuracy for 0 
min. if linear interpolation is used, but 5 min. as better if a logarithmic fit is used.  All of the 
samples confirm previous conclusions that red and green are more useful than blue readings for 
estimating PPA concentration.  For the remainder of the blind test trials the estimates from 
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linear interpolation of the 5 minute reading of the red and green samples will be used because 
they seem to be the most accurate for the greatest number of readings. 
Further research should probably look into better standardizing the rolls so that color 
values are more reproducible.  Experiments to optimize the region of accuracy, concerning PPA 
concentration, would be useful because these experiments show the greatest accuracy at high 
levels of PPA and ideally patients will have low levels of this product if their condition is well 
controlled.  This could probably be done by characterizing the reaction rate as a function of each 
reactant concentration as well as other factors such as pH. 
The blind creatinine (Cre) tests were carried out using the same commercially available 
test strips that were used to create the calibration curve.  These strips varied from batch to 
batch and so accuracy was best if strips from the same tube were used each time, which limited 
the number of repetitions of the blind test that could be done.  Therefore the analysis of these 
readings differs slightly from the PPA rolls in that they were normalized by a background 
reading, but could not be averaged over several runs.   Five unknowns were created and tested 
using the method previously described and the RGB values divided by the corresponding RGB 
values of their backgrounds.  A similar calibration chart had been created and fit with a line that 
served as the calibration equation to estimate the Cre concentration in each sample.  There is 
only a calibration for the strips at 5 min. because of the lack of color change at 0 min.  Because 
the fit was already linear, only one method was used to estimate the Cre concentration of each 
sample.  The estimates, actual values, and percent error are shown in Table 6.3.8 for the five 
unknowns. 
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sample 1 2 3 4 5 
red estimate 151.1158 101.004 278.9007 8.297318 90.98168 
green estimate 184.9217 119.9939 274.584 8.689068 101.4431 
blue estimate 123.9341 197.7033 271.4726 50.16487 13.28026 
actual 200 150 400 20 100 
% error red -24.442 -32.664 -30.275 -58.513 -9.018
%error green -7.539 -20.004 -31.354 -56.555 1.443 
%error blue -38.033 31.802 -32.132 150.824 -86.720
Table 6.3.8.  The estimates for the concentration of creatinine in mg/dL and the actual 
concentrations, as well as the percent errors for each estimate. 
From this evaluation, I conclude that the green reading leads to the best estimate of the 
creatinine concentration.  More repetitions of this test would be necessary to make more solid 
conclusions and the test strips themselves had a lot of variation in color from spot to spot on the 
same test strip, thus making measurements difficult.  Future work should improve the reliability 
and reproducibility of this test.  Of the three RGB colors, green exhibited the lowest percent 
error and thus should be kept in mind when further optimizing this test. 
For the final step of the proof-of-concept for the blind tests, PPA samples A, B, and C 
were paired with creatinine samples 4, 5, and 2, respectively, to create a ratio between the two 
that can be used to estimate a theoretical patient’s blood Phe value using the data found in 
literature.  A graph showing the line of best fit from data from literature correlating urine and 
blood values of the solutes of interest is shown above in Figure 6.3.4 and was used as an 
example of predicting blood Phe levels from measurements of urine PPA and Cre.  The results of 
these calculations are provided in Table 6.3.9. 
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ratio moles PPA/ mmoles Cre blood Phe conc. (mM) 
A/4 B/5 C/2 A/4 B/5 C/2 
Red 58.71 1.82 0.84 0.58 0.52 0.52 
Green 53.55 1.69 0.71 0.58 0.52 0.52 
Table 6.3.9.  Experimental estimates of the ratio of creatinine to PPA for several of the blind 
tests as well as their estimated blood phe levels for a pediatric PKU patient based on the 
correlation plot shown above in Figure 6.3.4. 
While the pairs of blind samples were chosen to give the greatest range of ratios, it 
seems that the PPA values chosen for the majority of the tests were too low for this calibration 
scheme to be very effective.  Most testing was done with PPA levels similar to that of a well 
controlled PKU patient or below so that sensitivity could be optimized; however, this means that 
most PKU patients do not have PPA levels this low and the calibration to blood Phe levels is not 
well equipped to handle these values.  This exercise only is meant to demonstrate the ability of 
the proposed series of measurements and calculations to estimate blood Phe from PKU patients 
from a urine sample. However, the chosen unknown PPA values were smaller than a PKU 
patient who would benefit from this test, which would be more applicable for patients with 




This research was focused on the development of an improved urine test method that 
could be used to estimate blood Phe concentration for patients with PKU.  The developed new 
test method was able to demonstrate an improvement over the previously developed ferric-
chloride-based urine test, Phenistix, by two orders of magnitude in sensitivity.  Out of many test 
substrates that were tried, white paper towel rolled, bound with parafilm, sliced into disks, and 
treated with Phenistix formula was the most successful at creating the greatest color difference 
over a wide range of PPA concentrations in a urine analog.  This test could detect PPA at 
concentrations as low as 5x10-6 M in synthetic urine and 5x10-5 M in human urine.  The test was 
also valid on synthetic urine that had been kept frozen for one week.  The improved test 
identified unknown concentrations of PPA and creatinine within reasonable margins of error 
given the large range of values.  The PPA test was more accurate at higher concentrations of 
PPA, which are more likely to occur in patients with moderately controlled PKU1.  Proof-of-
concept was shown for estimating the blood Phe levels of PKU patients using this noninvasive 
testing method.  Optimization of testing time, substrate composition and uniformity, and 
photographic conditions will likely lead to more accurate results.  Improvements of the 
creatinine strips will also be needed for improved test accuracy.  The need for a simple, 
inexpensive, non-invasive PKU monitoring test is great and this test is a step in the direction of 




8.1.  Optimization of Testing 
Several aspects of the test method can be optimized to increase its sensitivity and 
accuracy.  The formula that the test rolls are saturated with is identical to the original Phenistix 
formula, which was probably optimized for flat cellulose strips.  It is possible that a different 
concentration of each of the constituents will yield a better test for use with the paper-towel 
rolls, or similar substrate.  It would be ideal for there to be as much spread in the color values as 
possible within the range of interest, which is limited by Phe metabolism to PPA (does not occur 
below 0.3 mM plasma Phe) and renal clearance of PPA (maximum of 40-60 micromolar PPA, 
corresponding to 1.1-1.2 mM plasma Phe)33.  Making the color change as linear as possible 
within this range would make analysis more straightforward and improve accuracy.   
This test method was developed by taking color readings at five minute intervals from 0 
to 30 minutes. Five minutes or less was found to be the time best suited to give the greatest 
range of color values.  Taking more frequent readings, or even video, to find when the darkest 
color change is occurring could find a better time for taking measurements to optimize accuracy.  
The test strips themselves are currently made by hand and are subject to a certain level 
of variability in thickness and how tight they are rolled.  It would be ideal to find a way that 
ensures consistency in creation.  It also seems that how tightly the paper towel is rolled affects 
the color change, so this should be optimized for greatest color change in the range of interest 
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as well.  The pregnancy test polymer with oriented channels may be another manufacturing 
avenue to pursue. 
The light box is currently bulky and not conducive to mass-production.  A 3-D printable 
box should be developed for greatest usability and cost effectiveness.  The new design for the 
box should be as small and portable as possible while still maintaining controlled light 
conditions.  Batteries and LEDs will help to keep the device portable and light.  Changing the 
color of the LEDs from white to a specific wavelength relating to the color of the test substrates 
may also help to create more accurate readings. 
8.2.  Human Trials and Individual Calibration 
Literature search has found that the correlation between PPA levels in the urine and Phe 
levels in the blood vary greatly by age and by individual6.  Even when adjusted for age and 
creatinine level, it is difficult to create a calibration curve that would be acceptably reliable for 
all patients as a single population.  Future work should involve getting simultaneous blood and 
urine samples from PKU patients to create individualized calibration curves relating PPA, 
creatinine, and Phe in the fluids of interest.  The use of actual patients and clinicians will help to 
troubleshoot the test and determine its usefulness as an at-home blood Phe-level monitoring 
method. 
8.3.  App Development 
Currently, an app is used to get the RGB values from photographs of the samples, but all of 
the calculations are done in excel.  For patients to use this technology effectively it will have to 
be developed into an app that will do the calibration calculations for them and give them a 
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useful readout of an estimated blood Phe level.  It would be possible to combine this app with 
one used for tracking meals and grams of Phe consumed to control the patient’s condition as 
conveniently as possible. It would also be very useful for the app to enable test results to be 
automatically transmitted to the clinic used by the patient to provide nutritionists and 
physicians with this information to assist them in their efforts to help the patient control his or 
her blood Phe levels within a reasonable range on a daily basis. 
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Appendix: RGB graphs of tests 













































































































































































































































































































































































































































































































































































































Normalized synthetic urine calibration graph (not used for blind tests). Data taken over several 
days. 























y = -2.0401E-04ln(x) + 1.0152E-03
R² = 9.4492E-01

























Normalized human urine calibration graph (not used for blind tests). Data taken over several 
days. 
Top right hand logarithmic line of best fit corresponds to 0 mins, lower right corresponds to 
5mins.  
y = -2.4536E-04ln(x) + 1.1772E-03
R² = 9.5638E-01























y = -3.1617E-04ln(x) + 1.1159E-03
R² = 9.4729E-01
























y = -3E-04ln(x) + 0.0014
R² = 0.9945



























y = -4E-04ln(x) + 0.0017
R² = 0.9918




























Blind test calibration graphs. Top right hand logarithmic line of best fit corresponds to 0 mins, 
lower right corresponds to 5mins. 
y = -4E-04ln(x) + 0.0011
R² = 0.9729



























y = -1.6634E-04ln(x) + 8.2167E-04
R² = 9.1268E-01
























Creatinine test strips test, no light box, 1 year before deteriorated function noticed. 
y = -1.9511E-04ln(x) + 9.3685E-04
R² = 9.5742E-01























y = -2.7408E-04ln(x) + 9.2543E-04
R² = 9.2029E-01
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